CNMD vs EYPT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CNMD exhibits a stark divergence between its strong balance sheet health (Piotroski F-Score: 7/9) and its deteriorating operational performance. While the company maintains a stable financial foundation and a low Price-to-Sales ratio, it is plagued by a severe earnings collapse (-50% YoY) and a consistent track record of missing analyst estimates (0/4 beats in the last year). With the current price ($38.34) trading above the Graham Number ($33.66) and significantly above the growth-based intrinsic value ($10.57), the stock lacks a valuation catalyst despite a low forward P/E.
EYPT shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
CNMD vs EYPT: Head-to-Head Comparison
This page compares CONMED Corporation (CNMD) and EyePoint, Inc. (EYPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.